InsidersTradesSigma
Track the BioRestorative Therapies, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, BioRestorative Therapies, Inc. has published 81 public disclosures. Market capitalisation: €8.5m. The latest transaction was reported on 20 October 2025 (Attribution). Among the most active insiders: ALSTODT LANCE. The full history is free.
81
Insider Decl.
n/a
Thresholds
€623,619
65 ops.
Buy Volume
€15,987
4 ops.
Sell Volume
58Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 October 2025
Declarations81 total
11,719 shares@ US$1.6011.3% of flowComon StockSEC:0001021771-25-000141:0
15,625 shares@ US$1.6013.8% of flowCommon StockSEC:0001021771-25-000140:0
1,112 shares@ US$1.580.4% of flowCommon StockSEC:0001021771-24-000184:0
476 shares@ US$1.130.3% of flowCommon StockSEC:0001021771-24-000091:0
Canonical exit: 7 Jul 2024 (T+90)
17,193 shares@ US$1.3912.8% of flowCommon StockSEC:0001021771-24-000079:0
17,633 shares@ US$1.3913.3% of flowCommon StockSEC:0001021771-24-000077:0
73,959 shares@ US$1.2520.1% of flowCommon StockSEC:0001021771-24-000038:0
Canonical exit: 8 May 2024 (T+90)
36,374 shares@ US$1.3811.0% of flowCommon StockSEC:0001021771-24-000035:0
Canonical exit: 7 May 2024 (T+90)
250 shares@ US$1.8770.1% of flowCommon StockSEC:0001021771-23-000118:0
278 shares@ US$1.890.1% of flowCommon StockSEC:0001021771-23-000116:0
10,000 shares@ US$1.545.0% of flowCommon StockSEC:0001021771-23-000098:0
Canonical exit: 13 Dec 2023 (T+90)
2,200 shares@ US$1.702.4% of flowCommon StockSEC:0001021771-23-000096:0
Canonical exit: 14 Dec 2023 (T+90)
500 shares@ US$2.890.3% of flowCommon StockSEC:0001021771-23-000092:0
Canonical exit: 26 Oct 2023 (T+90)
800 shares@ US$1.53250.7% of flowCommon StockSEC:0001021771-23-000090:0
Canonical exit: 12 Dec 2023 (T+90)
2,887 shares@ US$1.963.1% of flowCommon StockSEC:0001021771-23-000088:0
Canonical exit: 5 Dec 2023 (T+90)
4,954 shares@ US$2.225.9% of flowCommon StockSEC:0001021771-23-000086:0
Canonical exit: 29 Nov 2023 (T+90)
1,000 shares@ US$2.800.6% of flowCommon StockSEC:0001140361-23-036665:0
Canonical exit: 25 Oct 2023 (T+90)
4,200 shares@ US$2.445.5% of flowCommon StockSEC:0001140361-23-036103:0
Canonical exit: 23 Oct 2023 (T+90)
747 shares@ US$3.561.4% of flowCommon StockSEC:0001021771-23-000034:0
Canonical exit: 29 Jun 2023 (T+90)
6,729 shares@ US$2.9210.7% of flowCommon StockSEC:0001021771-23-000028:0
6,729 shares@ US$2.9210.8% of flowCommon StockSEC:0001021771-23-000026:0
100 shares@ US$2.780.1% of flowCommon StockSEC:0001567619-23-004348:0
Canonical exit: 28 Feb 2023 (T+90)
374 shares@ US$2.990.6% of flowCommon StockSEC:0001567619-23-003891:0
374 shares@ US$2.990.6% of flowCommon StockSEC:0001567619-23-003875:0
400 shares@ US$3.10340.7% of flowCommon StockSEC:0001567619-23-001697:0
Canonical exit: 2 May 2023 (T+90)
25 of 81 declarations
关于 BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.（股票代码：BRTX）是一家在美国注册、在纳斯达克上市的再生医学公司。公司总部位于纽约州梅尔维尔，致力于开发干细胞疗法及相关产品，重点关注成人干细胞科学和转化医学。从股票分析师的角度来看，BRTX应被视为一家处于临床阶段的微市值生物技术公司，具有显著的二元风险，但如果其主要资产能继续推进临床和监管里程碑，也存在上行选择权。 该公司由专注于解决高发病率疾病中未满足医疗需求的科学家和研究人员创立。随着时间的推移，公司将其业务整合到长岛梅尔维尔，并在那里设有总部和实验室设施。BioRestorative的商业模式围绕两个核心项目展开。其椎间盘/脊柱项目，品牌名为brtxDISC，由BRTX-100主导，这是一种源自患者自身骨髓的自体间充质干细胞疗法，旨在治疗慢性椎间盘相关疼痛。其第二个平台ThermoStem通过涉及棕色脂肪组织生物学和相关外泌体的细胞方法，针对肥胖等代谢紊乱。 在竞争方面，BioRestorative在一个高度专业化且竞争激烈的再生医学领域运营，成功取决于临床差异化、知识产权实力、制造技术以及驾驭FDA途径的能力。可寻址市场巨大，特别是慢性脊柱疼痛和代谢疾病，但该公司仍处于商业化前阶段，因此尚未达到大型生物技术同行那样的规模、收入基础或去风险化程度。因此，投资者主要是在为科学执行而非当前的运营业绩提供资金。 近期发展至关重要。在2025年和2026年，BioRestorative强调了BRTX-100扩展的2期数据、在美国15个地点完成一项随机、双盲、假手术对照的2期试验的患者招募，以及与FDA的持续互动。公司还完成了5 million美元的公开发行，并一直在谨慎管理资本，这对于开发阶段的生物技术公司来说是典型的。在2026年4月，公司宣布与203 Creates建立战略合作，以构建和商业化一个生物美容平台，这表明公司正在努力将其商业叙事扩展到核心临床项目之外。对于投资者而言，BRTX将早期再生医学的敞口与长期价值创造潜力相结合，但也伴随着重大的临床、融资和执行风险。
